HKD 48.6
(-1.02%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 2.42 Billion CNY | 0.34% |
2022 | 2.42 Billion CNY | 42.0% |
2021 | 1.7 Billion CNY | 92.82% |
2020 | 884.41 Million CNY | 181.15% |
2019 | 314.57 Million CNY | -85.96% |
2018 | 2.24 Billion CNY | 214.1% |
2017 | 713.46 Million CNY | 17.36% |
2016 | 607.94 Million CNY | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q2 | 2.33 Billion CNY | 0.0% |
2023 Q4 | 2.42 Billion CNY | 0.0% |
2023 FY | 2.42 Billion CNY | 0.34% |
2023 Q2 | 2.31 Billion CNY | 0.0% |
2022 Q2 | 2.15 Billion CNY | 0.0% |
2022 Q4 | 2.42 Billion CNY | 0.0% |
2022 FY | 2.42 Billion CNY | 42.0% |
2021 Q4 | 1.7 Billion CNY | 0.0% |
2021 FY | 1.7 Billion CNY | 92.82% |
2021 Q2 | 958.3 Million CNY | 0.0% |
2020 FY | 884.41 Million CNY | 181.15% |
2020 Q2 | 493.32 Million CNY | 0.0% |
2020 Q4 | 884.41 Million CNY | 0.0% |
2019 Q2 | 2.69 Billion CNY | 0.0% |
2019 FY | 314.57 Million CNY | -85.96% |
2019 Q4 | 314.57 Million CNY | 0.0% |
2018 Q4 | 2.24 Billion CNY | 0.0% |
2018 FY | 2.24 Billion CNY | 214.1% |
2017 FY | 713.46 Million CNY | 17.36% |
2016 FY | 607.94 Million CNY | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Uni-Bio Science Group Limited | 152.81 Million HKD | -1489.97% |
CK Life Sciences Int'l., (Holdings) Inc. | 7.05 Billion HKD | 65.575% |